IFNB1 Protein (AA 22-187)

N° du produit ABIN8056988

Protéine Recombinant IFNB1 exprimée dans HEK-293 Cells.

Aperçu rapide pour IFNB1 Protein (AA 22-187) (ABIN8056988)

Antigène: IFNB1 (Interferon, beta 1, Fibroblast (IFNB1))

Type de proteíne: Recombinant

Origine: Humain

Source: HEK-293 Cells

Application: Immunogen (Imm)

Pureté: > 95 % as determined by reducing SDS-PAGE.

Détail du produit

Attributs du protein: AA 22-187

Fonction: Recombinant Human IFN-β Protein(Halo Tag)

Séquence: Met22-Asn187

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1.0 EU/mg of the protein as determined by the LAL method

Biological Activity Comment: Not validated for activity

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.5 mg/mL. Concentration is measured by UV-Vis.

Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with 5 % Trehalose and 5 % Mannitol.

Stock: 4 °C,-20 °C,-80 °C

Stockage commentaire: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Date de péremption: 12 months

Détail du antigène

Antigène: IFNB1 (Interferon, beta 1, Fibroblast (IFNB1))

Autre désignation: IFN-beta

Sujet: Interferon beta,IFNB,Fibroblast interferon,Interferons (IFNs) are natural glycoproteins belonging to the cytokine superfamily and are produced by the cells of the immune system of most vertebrates in response to challenges by foreign agents such as viruses, parasites, and tumor cells. Interferon-beta (IFN beta) is an extracellular protein mediator of host defense and homeostasis. IFN beta has well-established direct antiviral, antiproliferative, and immunomodulatory properties. Recombinant IFN beta is approved for the treatment of relapsing-remitting multiple sclerosis. The recombinant IFN beta protein has the theoretical potential to either treat or causes autoimmune neuromuscular disorders by altering the complicated and delicate balances within the immune system networks. It is the most widely prescribed disease-modifying therapy for multiple sclerosis (MS). Large-scale clinical trials have established the clinical efficacy of IFN beta in reducing relapses and slowing disease progression in relapsing-remitting MS. IFN beta therapy was shown to be comparably beneficial for opticospinal MS (OSMS) and conventional MS in Japanese. IFN beta is effective in reducing relapses in secondary progressive MS and may have a modest effect in slowing disability progression. In addition to the common antiviral activity, IFN beta also induces increased production of the p53 gene product which promotes apoptosis and thus has a therapeutic effect against certain cancers. The role of IFN-beta in bone metabolism could warrant its systematic evaluation as a potential adjunct to therapeutic regimens of osteolytic diseases. Furthermore, IFN beta might play a beneficial role in the development of chronic progressive CNS inflammation.

Poids moléculaire:

Calculated MW: 51.1 kDa

Observed MW: 55 kDa

ID gène: 3456

UniProt: P01574

Pathways: Signalistation JAK/STAT, TCR Signaling, Signalisation TLR, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Positive Regulation of Endopeptidase Activity, Hepatitis C, Autophagy, Inflammasome